Efficacy of a Multiple-Indication Antiviral Herbal Drug (Saliravira®) for Covid-19 Outpatients: A Pre-Clinical and Randomized Clinical Trial Study

Efficacy of a Multiple-Indication Antiviral Herbal Drug (Saliravira®) for Covid-19 Outpatients: A Pre-Clinical and Randomized Clinical Trial Study Publisher Pubmed

Khorshiddoust RR¹ ; Khorshiddoust SR¹ ; Hosseinabadi T² ; Mottaghitalab F¹ ; Mokhtari F¹ ; Azadinia F¹ ; Mozdarani H³ ; Shabani M⁴ ; Emadikouchak H⁵ ; Taheri B⁶ ; Khanijuyabad F¹ ; Kashani MA¹ ; Sadoughi A⁷ ; Zamanizadeh S⁷ Show All Authors

Khorshiddoust RR¹
Khorshiddoust SR¹
Hosseinabadi T²
Mottaghitalab F¹
Mokhtari F¹
Azadinia F¹
Mozdarani H³
Shabani M⁴
Emadikouchak H⁵
Taheri B⁶
Khanijuyabad F¹
Kashani MA¹
Sadoughi A⁷
Zamanizadeh S⁷
Maddah H⁷
Aminzadeh M⁷
Khanaki M⁷
Saremi S⁷
Rad AP⁷
Fatehi A⁸
Rad MG¹
Haftbaradaran M⁹
Khosroshahi M⁹
Sadeghi M⁹
Aminnayeri M⁷
Jafari S⁵
Ghiasvand F⁵
Seifi A⁵
Ghaderkhani S⁵
Manshadi SAD⁵
Salehi M⁵
Abbasian L⁵
Hasannezhad M⁵
Meidani M⁵
Hajiabdolbaghi M⁵
Ahmadinejad Z⁵
Parash M⁵
Sedighi Z⁵
Mohammadian A⁵

Show Affiliations

1. R&D Group, MIM Pharma, Oslo, Norway
2. Department of Pharmacognosy and Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3. Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
4. Department of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
5. Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
6. Nexus & HSE Center, Amirkabir University of Technology, Tehran, Iran
7. Aramesh Multi-Professional Pain Clinic, Tehran, Iran
8. Department of Industrial Engineering and Management Systems, Amirkabir University of Technology, Tehran, Iran
9. MIM Daroo, Tehran, Iran

Source: Biomedicine and Pharmacotherapy Published:2022

Abstract

Background: The scientific researches on COVID-19 pandemic topics are headed to an explosion of scientific literature. Despite these global efforts, the efficient treatment of patients is an in-progress challenge. Based on a meta-study of published shreds of evidence about compounds and their botanic sources in the last six decades, a novel multiple-indication herbal compound (Saliravira®) has been developed. Based on the antiviral, anti-inflammatory, and immune-enhancing properties of its ingredients, we hypothesized that Saliravira® has the potential to act as an antiviral agent, accelerate treatment, and reduce undesirable effects of COVID-19. Methods: In this randomized, controlled, open-label clinical trial, COVID-19 outpatients were included by RT-PCR test or diagnosis of physicians according to the symptoms. Participants were randomly divided into intervention and control groups to receive Saliravira® package plus routine treatments of COVID-19 or routine treatments of COVID-19 alone, respectively. Saliravira® package includes tablets, nasal-sinuses spray, oral-pharynx spray, and inhaler drops. The treatment was for 10 days and followed up till 23 days after admission. Results: On the 8th day, the “mean reduction rates” of viral load of the patients in the intervention group was 50% lower compared to the control group with a p-value < 0.05. The improvement of 10 out of 14 COVID-19 symptoms in the intervention group was significantly accelerated. The mean treatment duration of patients in the intervention group was 4.9 days less than the control group. In addition, no patients in the intervention group were hospitalized compared to 28% of the control group needed to be hospitalized. © 2022

2. Selective Serotonin Reuptake Inhibitors: New Hope in the Fight Against Covid-19, Frontiers in Pharmacology (2022)

3. Genomic Surveillance of Sars-Cov-2 Strains Circulating in Iran During Six Waves of the Pandemic, Influenza and other Respiratory Viruses (2023)

Experts (# of related papers)

View all Related Experts

Nazanin Zahra Shafiei Jandaghi (1)

Pantea Izadi (1)

Style	Citing Format
MLA	Khorshiddoust RR, et al.. "Efficacy of a Multiple-Indication Antiviral Herbal Drug (Saliravira®) for Covid-19 Outpatients: A Pre-Clinical and Randomized Clinical Trial Study." Biomedicine and Pharmacotherapy, vol. 149, no. , 2022, pp. -.
APA	Khorshiddoust RR, Khorshiddoust SR, Hosseinabadi T, Mottaghitalab F, Mokhtari F, Azadinia F, Mozdarani H, Shabani M, Emadikouchak H, Taheri B, Khanijuyabad F, Kashani MA, Sadoughi A, Zamanizadeh S, Maddah H, Aminzadeh M, Khanaki M, Saremi S, Rad AP, ... Mohammadian A (2022). Efficacy of a Multiple-Indication Antiviral Herbal Drug (Saliravira®) for Covid-19 Outpatients: A Pre-Clinical and Randomized Clinical Trial Study. Biomedicine and Pharmacotherapy, 149(), -.
Chicago	Khorshiddoust RR, Khorshiddoust SR, Hosseinabadi T, Mottaghitalab F, Mokhtari F, Azadinia F, Mozdarani H, et al.. "Efficacy of a Multiple-Indication Antiviral Herbal Drug (Saliravira®) for Covid-19 Outpatients: A Pre-Clinical and Randomized Clinical Trial Study." Biomedicine and Pharmacotherapy 149, no. (2022): -.
Harvard	Khorshiddoust RR et al. (2022) 'Efficacy of a Multiple-Indication Antiviral Herbal Drug (Saliravira®) for Covid-19 Outpatients: A Pre-Clinical and Randomized Clinical Trial Study', Biomedicine and Pharmacotherapy, 149(), pp. -.
Vancouver	Khorshiddoust RR, Khorshiddoust SR, Hosseinabadi T, Mottaghitalab F, Mokhtari F, Azadinia F, et al.. Efficacy of a Multiple-Indication Antiviral Herbal Drug (Saliravira®) for Covid-19 Outpatients: A Pre-Clinical and Randomized Clinical Trial Study. Biomedicine and Pharmacotherapy. 2022;149():-.
BibTex	@article{ author = {Khorshiddoust RR and Khorshiddoust SR and Hosseinabadi T and Mottaghitalab F and Mokhtari F and Azadinia F and Mozdarani H and Shabani M and Emadikouchak H and Taheri B and Khanijuyabad F and Kashani MA and Sadoughi A and Zamanizadeh S and Maddah H and Aminzadeh M and Khanaki M and Saremi S and Rad AP and Fatehi A and Rad MG and Haftbaradaran M and Khosroshahi M and Sadeghi M and Aminnayeri M and Jafari S and Ghiasvand F and Seifi A and Ghaderkhani S and Manshadi SAD and Salehi M and Abbasian L and Hasannezhad M and Meidani M and Hajiabdolbaghi M and Ahmadinejad Z and Parash M and Sedighi Z and Mohammadian A}, title = {Efficacy of a Multiple-Indication Antiviral Herbal Drug (Saliravira®) for Covid-19 Outpatients: A Pre-Clinical and Randomized Clinical Trial Study}, journal = {Biomedicine and Pharmacotherapy}, volume = {149}, number = {}, pages = {-}, year = {2022} }
RIS	TY - JOUR AU - Khorshiddoust RR AU - Khorshiddoust SR AU - Hosseinabadi T AU - Mottaghitalab F AU - Mokhtari F AU - Azadinia F AU - Mozdarani H AU - Shabani M AU - Emadikouchak H AU - Taheri B AU - Khanijuyabad F AU - Kashani MA AU - Sadoughi A AU - Zamanizadeh S AU - Maddah H AU - Aminzadeh M AU - Khanaki M AU - Saremi S AU - Rad AP AU - Fatehi A AU - Rad MG AU - Haftbaradaran M AU - Khosroshahi M AU - Sadeghi M AU - Aminnayeri M AU - Jafari S AU - Ghiasvand F AU - Seifi A AU - Ghaderkhani S AU - Manshadi SAD AU - Salehi M AU - Abbasian L AU - Hasannezhad M AU - Meidani M AU - Hajiabdolbaghi M AU - Ahmadinejad Z AU - Parash M AU - Sedighi Z AU - Mohammadian A TI - Efficacy of a Multiple-Indication Antiviral Herbal Drug (Saliravira®) for Covid-19 Outpatients: A Pre-Clinical and Randomized Clinical Trial Study JO - Biomedicine and Pharmacotherapy VL - 149 IS - SP - EP - PY - 2022 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract